文献速递肝病消化道肿瘤与早癌

常规风险评分在社区人群中预测肝硬化相关并发症的表现

Performance of routine risk scores for predicting cirrhosis-related morbidity in the community.
PubMed 文献 · J Hepatol · 2022-03-07

本研究采用两阶段设计,系统综述识别20种基于常规肝功能血液检查的风险评分,并在英国生物银行197,509名有慢性肝病危险因素的参与者中验证其预测10年肝硬化相关并发症(住院或肝细胞癌)的能力。结果显示APRI(C指数0.804)和FIB-4(C指数0.780)表现最佳,加入遗传数据仅轻微改善C指数至0.809。

要点

  • 在社区人群中,APRI和FIB-4可用于估算10年肝硬化相关并发症风险。
  • APRI评分超过第90、95、99百分位者10年累积发生率分别为3.30%、5.42%、14.83%。
  • 加入已知遗传风险位点仅增加<5%的新预后信息,C指数仅从0.804升至0.809。

核心结论

  • 基于常规血液检查的可及性风险评分(尤其是APRI和FIB-4)可重新用于估算社区人群10年肝硬化相关并发症风险。
  • 遗传数据仅轻微改善预测性能。

研究设计与样本

  • 两阶段研究设计:第一阶段系统综述识别基于常规肝功能血液检查的风险评分;第二阶段在英国生物银行有慢性肝病危险因素的197,509名参与者中验证。
  • 肝硬化相关并发症定义为因肝硬化住院或出现肝细胞癌。
  • 采用Wolbers C指数、Harrell充分性指数和累积发生率曲线评估判别能力。

主要发现

  • 第一阶段系统综述共识别20种风险评分。
  • 第二阶段197,509名参与者中,10年肝硬化相关并发症累积发生率为0.58%(95% CI 0.54-0.61),共1,110例事件。
  • 表现最佳的风险评分为APRI(C指数0.804;95% CI 0.788-0.820)和FIB-4(C指数0.780;95% CI 0.764-0.795)。
  • APRI评分超过第90、95、99百分位的参与者10年累积发生率分别为3.30%、5.42%、14.83%。
  • 加入已知遗传风险位点仅增加<5%的新预后信息,C指数仅从0.804升至0.809。

关键数值与推荐

  • APRI C指数0.804(95% CI 0.788-0.820);FIB-4 C指数0.780(95% CI 0.764-0.795)。
  • APRI超过第90百分位者10年累积发生率3.30%;超过第95百分位者5.42%;超过第99百分位者14.83%。
  • 加入遗传数据后APRI的C指数从0.804升至0.809,增加<5%新预后信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Models predicting an individual's 10-year risk of cirrhosis complications have not been developed for a community setting. Our objectives were to assess the performance of existing risk scores - both with and without genetic data - for predicting cirrhosis complications in the community. METHODS: We used a 2-stage study design. In stage 1, a systematic review was conducted to identify risk scores derived from routine liver blood tests that have demonstrated prior ability to predict cirrhosis-related complication events. Risk scores identified from stage 1 were tested in a UK Biobank subgroup, comprising participants with a risk factor for chronic liver disease (stage 2). Cirrhosis complications were defined as hospitalisation for liver cirrhosis or presentation with hepatocellular carcinoma. Discrimination of risk scores with and without genetic data was assessed using the Wolbers C-index, Harrell's adequacy index, and cumulative incidence curves. RESULTS: Twenty risk scores were identified from the stage-1 systematic review. For stage-2, 197,509 UK biobank participants were selected. The cumulative incidence of cirrhosis complications at 10 years was 0.58%; 95% CI 0.54-0.61 (1,110 events). The top performing risk scores were aspartate aminotransferase-to-platelet ratio index (APRI: C-index 0.804; 95% CI 0.788-0.820) and fibrosis-4 index (FIB-4: C-index 0.780; 95% CI 0.764-0.795). The 10-year cumulative incidences of cirrhosis complications for participants with an APRI score exceeding the 90th, 95th and 99th percentile were 3.30%, 5.42% and 14.83%, respectively. Inclusion of established genetic risk loci associated with cirrhosis added <5% of new prognostic information to the APRI score and improved the C-index only minimally (i.e. from 0.804 to 0.809). CONCLUSIONS: Accessible risk scores derived from routine blood tests (particularly APRI and FIB-4) can be repurposed to estimate 10-year risk of cirrhosis morbidity in the community. Genetic data improves performance only minimally. LAY SUMMARY: New approaches are needed in community settings to reduce the late diagnosis of chronic liver disease. Thus, in a community cohort, we assessed the ability of 20 routine risk scores to predict 10-year risk of cirrhosis-related complications. We show that 2 routine risk scores in particular - "APRI" and "FIB-4" - could be repurposed to estimate an individual's 10-year risk of cirrhosis-related morbidity. Adding genetic risk factor information to these scores only modestly improved performance.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Innes H, Morling JR, Buch S, et al. Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. J Hepatol. 2022. PMID: 35271950. doi:10.1016/j.jhep.2022.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。